Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Celecoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 14/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.98 |
| ▸ | PDPK1 | O15530 | 7/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.98 |
| ▸ | PTGES | O14684 | 1/20 | 0.98 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | PDE5A | O76074 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CA3 | P07451 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Celecoxib SCHEMBL3708 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3669597 | 0.99 | PTGS2 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL19212458 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| SCHEMBL5673015 | 0.98 | PDPK1 (1.00) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL28441251 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL1982868 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL354683 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL3785427 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL6600270 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES | |
| Celecoxib SCHEMBL1981887 | 0.98 | PTGS2 (0.98) | PTGS2PTGS1PDPK1CYP2C9PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635021-A | Opioid-free compositions for narcotics applications and related methods and systems | 威培沃克斯护理麻醉公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116098731-A | Modeling method of in-vivo visualization animal model for coronary microcirculation disturbance disease | 新疆医科大学第一附属医院 | 2023-05-12 | — | — | CN | claimed |
| CN-118105434-A | Preparation method of blackberry lily fraction and application thereof in preparation of anti-herpes simplex virus type 1 medicine | 深圳大学 | 2024-05-31 | — | — | CN | disclosed |
| CN-116515908-B | Method for establishing RPE65 gene editing model dog | 苏州启辰生物科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-113116847-B | Gastric retention tablet | 广州玻思韬控释药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113116850-B | Gastric retention tablet | 广州玻思韬控释药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-113116845-B | Gastric retention tablet | 广州玻思韬控释药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-113116846-B | Gastric retention tablet | 广州玻思韬控释药业有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117717566-A | Application of miR22 or miR 22-exosome of miR22 high-expression MSC in medicine for treating eye diseases | 天津医科大学眼科医院 | 2024-03-19 | — | — | CN | disclosed |
| CN-113116839-B | Gastric retention tablet | 广州玻思韬控释药业有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117281948-A | High-elasticity degradable nasal cavity filling material and preparation method thereof | 山东省科学院新材料研究所 | 2023-12-26 | — | — | CN | disclosed |
| CN-113941002-A | Slow-release drug delivery system for small-molecule drugs | 南京清普生物科技有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-113813315-A | Traditional Chinese medicine composition for relieving asthenopia and xerophthalmia, application thereof and prepared eye mask | 上海市光华中西医结合医院 | 2021-12-21 | — | — | CN | disclosed |
| CN-112996487-A | Rapidly disintegrating oral film matrix | 疗愈药物控股公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-112870205-A | Eutectic mixture of celecoxib and milnacipran hydrochloride, pharmaceutical composition containing eutectic mixture, and preparation method and application of eutectic mixture | 江苏谛奇医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112870205-A | Eutectic mixture of celecoxib and milnacipran hydrochloride, pharmaceutical composition containing eutectic mixture, and preparation method and application of eutectic mixture | 江苏谛奇医药科技有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112807315-A | Celecoxib and tapentadol hydrochloride eutectic mixture, pharmaceutical composition containing same, and preparation method and application thereof | 江苏谛奇医药科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-112807315-A | Celecoxib and tapentadol hydrochloride eutectic mixture, pharmaceutical composition containing same, and preparation method and application thereof | 江苏谛奇医药科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| CN-105744983-B | Device and method for sustained release of therapeutic agents of low water solubility in solubilizing agents | 纳米医学系统公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-2392319-A1 | Pharmaceutical compositions of co-crystals of tramadol and coxibs | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-12-07 | — | — | EP | disclosed |